

Timothy M Block

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2559146/publications.pdf>

Version: 2024-02-01

57
papers

4,516
citations

159585
30
h-index

149698
56
g-index

62
all docs

62
docs citations

62
times ranked

4881
citing authors

#	ARTICLE	IF	CITATIONS
1	Host RNA quality control as a hepatitis B antiviral target. <i>Antiviral Research</i> , 2021, 186, 104972.	4.1	7
2	Hepatoselective Dihydroquinolizinone Bis-acids for HBsAg mRNA Degradation. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1130-1136.	2.8	12
3	Prospects for the Global Elimination of Hepatitis B. <i>Annual Review of Virology</i> , 2021, 8, 437-458.	6.7	26
4	The Dihydroquinolizinone Compound RG7834 Inhibits the Polyadenylase Function of PAPD5 and PAPD7 and Accelerates the Degradation of Matured Hepatitis B Virus Surface Protein mRNA. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	14
5	A global scientific strategy to cure hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 545-558.	8.1	342
6	Do hepatitis B virus surface antigens have any role in viral carcinogenesis?. <i>Hepatology</i> , 2018, 68, 801-803.	7.3	2
7	Enhancing the antiviral potency of ER α -glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo. <i>Antiviral Research</i> , 2018, 150, 112-122.	4.1	26
8	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018, 67, 1127-1131.	7.3	70
9	HBsAg mRNA degradation induced by a dihydroquinolizinone compound depends on the HBV posttranscriptional regulatory element. <i>Antiviral Research</i> , 2018, 149, 191-201.	4.1	43
10	Implications of Circulating Hepatitis B Virus RNA Levels in Assessment of Response to Antiviral Therapy. <i>Current Hepatology Reports</i> , 2018, 17, 451-458.	0.9	0
11	Application of the Doylestown algorithm for the early detection of hepatocellular carcinoma. <i>PLoS ONE</i> , 2018, 13, e0203149.	2.5	10
12	The hepatitis B epidemic and the urgent need for cure preparedness. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 517-518.	17.8	20
13	Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B. <i>Antiviral Research</i> , 2018, 158, 185-198.	4.1	53
14	Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics. <i>Clinical Infectious Diseases</i> , 2017, 64, 1283-1288.	5.8	19
15	Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA. <i>PLoS Pathogens</i> , 2017, 13, e1006296.	4.7	107
16	A historical perspective on the discovery and elucidation of the hepatitis B virus. <i>Antiviral Research</i> , 2016, 131, 109-123.	4.1	24
17	The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma. <i>Cancer Prevention Research</i> , 2016, 9, 172-179.	1.5	48
18	Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care: Table 1.. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv359.	6.3	14

#	ARTICLE	IF	CITATIONS
19	Abstract 4934: Detection of HBV-host junction DNA sequences in urine of patients with hepatocellular carcinoma. , 2016, , .		2
20	Evolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection. Gastroenterology and Hepatology, 2016, 12, 679-689.	0.1	1
21	Article Commentary: Viral Resistance of MOGS-CDG Patients Implies a Broad-Spectrum Strategy against Acute Virus Infections. Antiviral Therapy, 2015, 20, 257-259.	1.0	19
22	Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States. Hepatology, 2015, 62, 1339-1341.	7.3	33
23	Present and future therapies of hepatitis B: From discovery to cure. Hepatology, 2015, 62, 1893-1908.	7.3	269
24	Differential methylation of the promoter and first exon of the <i>RASSF1A</i> gene in hepatocarcinogenesis. Hepatology Research, 2015, 45, 1110-1123.	3.4	31
25	Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues. Scientific Reports, 2015, 5, 10478.	3.3	41
26	Inhibition of Endoplasmic Reticulum-Resident Glucosidases Impairs Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63 Spike Protein-Mediated Entry by Altering the Glycan Processing of Angiotensin I-Converting Enzyme 2. Antimicrobial Agents and Chemotherapy, 2015, 59, 206-216.	3.2	63
27	Glycosylation and Liver Cancer. Advances in Cancer Research, 2015, 126, 257-279.	5.0	128
28	Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Research, 2015, 121, 69-81.	4.1	65
29	STING Agonists Induce an Innate Antiviral Immune Response against Hepatitis B Virus. Antimicrobial Agents and Chemotherapy, 2015, 59, 1273-1281.	3.2	93
30	An interferon-beta promoter reporter assay for high throughput identification of compounds against multiple RNA viruses. Antiviral Research, 2014, 107, 56-65.	4.1	18
31	Chronic hepatitis B: What should be the goal for new therapies?. Antiviral Research, 2013, 98, 27-34.	4.1	112
32	Total serum glycan analysis is superior to lectin-FLISA for the early detection of hepatocellular carcinoma. Proteomics - Clinical Applications, 2013, 7, 690-700.	1.6	30
33	Antiviral therapies targeting host ER alpha-glucosidases: Current status and future directions. Antiviral Research, 2013, 99, 251-260.	4.1	98
34	Design and synthesis of N-alkyldeoxynojirimycin derivatives with improved metabolic stability as inhibitors of BVDV and Tacaribe virus. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4258-4262.	2.2	10
35	Inhibition of Hepatitis B Virus Replication by the Host Zinc Finger Antiviral Protein. PLoS Pathogens, 2013, 9, e1003494.	4.7	204
36	Alpha-Interferon Suppresses Hepadnavirus Transcription by Altering Epigenetic Modification of cccDNA Minichromosomes. PLoS Pathogens, 2013, 9, e1003613.	4.7	135

#	ARTICLE	IF	CITATIONS
37	Imino sugar glucosidase inhibitors as broadly active anti-filovirus agents. <i>Emerging Microbes and Infections</i> , 2013, 2, 1-7.	6.5	21
38	Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4277-4288.	3.2	194
39	The innate immune response to hepatitis B virus infection: Implications for pathogenesis and therapy. <i>Antiviral Research</i> , 2012, 96, 405-413.	4.1	58
40	Characterization of the Host Factors Required for Hepadnavirus Covalently Closed Circular (ccc) DNA Formation. <i>PLoS ONE</i> , 2012, 7, e43270.	2.5	49
41	Production and Function of the Cytoplasmic Deproteinized Relaxed Circular DNA of Hepadnaviruses. <i>Journal of Virology</i> , 2010, 84, 387-396.	3.4	113
42	The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: Notes from a recent workshop. <i>Cancer Biomarkers</i> , 2008, 4, 19-33.	1.7	41
43	Molecular Virology of Hepatitis B Virus for Clinicians. <i>Clinics in Liver Disease</i> , 2007, 11, 685-706.	2.1	151
44	Characterization of the Intracellular Deproteinized Relaxed Circular DNA of Hepatitis B Virus: an Intermediate of Covalently Closed Circular DNA Formation. <i>Journal of Virology</i> , 2007, 81, 12472-12484.	3.4	267
45	Does Rapid Oligomerization of Hepatitis B Envelope Proteins Play a Role in Resistance to Proteasome Degradation and Enhance Chronicity?. <i>DNA and Cell Biology</i> , 2006, 25, 165-170.	1.9	13
46	GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2005, 43, 1007-1012.	3.7	321
47	Surrogate markers of efficacy for medical treatment of viral hepatitis. <i>Biotechnology Healthcare</i> , 2004, 1, 42-8.	0.2	1
48	Molecular viral oncology of hepatocellular carcinoma. <i>Oncogene</i> , 2003, 22, 5093-5107.	5.9	463
49	Herpes simplex virus type 1 infection prevents detachment of nerve growth factor-differentiated PC12 cells in culture. <i>Journal of General Virology</i> , 2002, 83, 1591-1600.	2.9	14
50	Synovial stimulatory protein fragments copurify with woodchuck hepatitis virus: Implications for the etiology of arthritis in chronic hepatitis B virus infection. <i>Arthritis and Rheumatism</i> , 2001, 44, 486-487.	6.7	11
51	Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: Therapeutic implications. <i>Hepatology</i> , 2001, 33, 1488-1495.	7.3	65
52	Hepatitis B Virus MHBs Antigen Is Selectively Sensitive to Glucosidase-Mediated Processing in the Endoplasmic Reticulum. <i>DNA and Cell Biology</i> , 2001, 20, 647-656.	1.9	15
53	Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin (antivirals/glycosylation). <i>World Scientific Series in 20th Century Biology</i> , 2000, , 552-556.	0.1	0
54	Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. <i>Nature Medicine</i> , 1998, 4, 610-614.	30.7	154

#	ARTICLE	IF	CITATIONS
55	Î±-Glucosidase inhibitors as potential broad based anti-viral agents. FEBS Letters, 1998, 430, 17-22.	2.8	251
56	Role of Glycan Processing in Hepatitis B Virus Envelope Protein Trafficking. Advances in Experimental Medicine and Biology, 1998, 435, 207-216.	1.6	10
57	Evidence That N-Linked Glycosylation Is Necessary for Hepatitis B Virus Secretion. Virology, 1995, 213, 660-665.	2.4	88